Oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), protein kinase B
(PKB/AKT), and mammalian target of rapamycin (mTOR) pathway is a frequent event in …

Tumor cells promote the recruitment of immunosuppressive neutrophils, a subset of myeloid
cells driving immune suppression, tumor proliferation, and treatment resistance …

Patients with castration-resistant prostate cancer inevitably acquire resistance to
antiandrogen therapies in part because of androgen receptor (AR) mutations or splice …

Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …

We integrated the genomic sequencing of 1,918 breast cancers, including 1,501 hormone
receptor-positive tumors, with detailed clinical information and treatment outcomes. In 692 …

Tumor molecular profiling is a fundamental component of precision oncology, enabling the
identification of genomic alterations in genes and pathways that can be targeted …

From a clinical, morphological and molecular perspective, prostate cancer is a
heterogeneous disease. Primary prostate cancers are often multifocal, having …

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Transcription factors (TFs) represent a major class of therapeutic targets for the treatment of
human diseases including cancer. Although the biological functions and even crystal …

Emerging evidence indicates that various cancers can gain resistance to targeted therapies
by acquiring lineage plasticity. Although various genomic and transcriptomic aberrations …